TY - JOUR
T1 - Neonatal susceptibility and immunity to major bacterial pathogens
AU - Ferrieri, Patricia
PY - 1990/5
Y1 - 1990/5
N2 - Neonatal bacterial sepsis has continued in this decade to contribute significantly to neonatal mortality and morbidity and is a critical determinant of outcome in infants of very low birth weight despite the availability of antibiotics. The group B Streptococcus and Escherichia coli are the predominant pathogens for the newborn infant. Studies on the epidemiology, microbiology, and immunology of group B streptococcal disease are more extensive than those on E. coli disease. Type-specific antibodies, polymorphonuclear leukocytes, and complement are integral to immunity against group B Streptococcus, and experimental data are presented to support the importance of these components. The newborn infant is handicapped by temporary deficiencies in host defenses, and approaches for restoring immunocompetence, such as immunization of the mother or passive administration of intravenous immunoglobulins or other immune factors, are presented for consideration. Further studies are required to demonstrate the safety, feasibility, and efficacy of these approaches.
AB - Neonatal bacterial sepsis has continued in this decade to contribute significantly to neonatal mortality and morbidity and is a critical determinant of outcome in infants of very low birth weight despite the availability of antibiotics. The group B Streptococcus and Escherichia coli are the predominant pathogens for the newborn infant. Studies on the epidemiology, microbiology, and immunology of group B streptococcal disease are more extensive than those on E. coli disease. Type-specific antibodies, polymorphonuclear leukocytes, and complement are integral to immunity against group B Streptococcus, and experimental data are presented to support the importance of these components. The newborn infant is handicapped by temporary deficiencies in host defenses, and approaches for restoring immunocompetence, such as immunization of the mother or passive administration of intravenous immunoglobulins or other immune factors, are presented for consideration. Further studies are required to demonstrate the safety, feasibility, and efficacy of these approaches.
UR - http://www.scopus.com/inward/record.url?scp=0025310867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025310867&partnerID=8YFLogxK
U2 - 10.1093/clinids/12.Supplement_4.S394
DO - 10.1093/clinids/12.Supplement_4.S394
M3 - Article
C2 - 2194266
AN - SCOPUS:0025310867
SN - 0162-0886
VL - 12
SP - S394-S400
JO - Reviews of infectious diseases
JF - Reviews of infectious diseases
ER -